Plasma Protein Therapeutic Market

Plasma Protein Therapeutic Market by Products (Immunoglobulin, Albumin, and Factor VIII), Applications (Primary Immunodeficiency Disorder, Hemophilia, Idiopathic Thrombocytopenic Purpura, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2180
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 214
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global plasma protein therapeutic market size is projected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the plasma product approval across numerous applications, increased R&D activities, and a significant demand for innovative treatment solutions.

Plasma Protein Therapeutic Market

Plasma-derived and recombinant analogue therapies are examples of plasma protein therapeutics. Bleeding disorders, immunological deficiencies, lung disorders, neurological disorders, shock and trauma, liver cirrhosis, and infectious diseases such as tetanus, hepatitis, and rabies are among the diseases that can be treated with plasma protein therapeutics. Plasma protein therapeutics include immunoglobulin, albumin, coagulation factors, and alpha-1 proteinase inhibitors. Life expectancy has increased as a result of technological breakthroughs, advantageous reimbursement policies, and a better standard of living, contributing to the rise in the senior population. The market penetration of plasma proteins is predicted to expand as new products with clinical benefits such as better efficacy and easy sample plasma extraction techniques are developed.

Manufacturers are focusing on innovative plasma-derived products for the diagnosis of neuropathic pain, myasthenia gravis, and post-polio syndrome among other neurological diseases. Albumin is also being tested in clinical trials to treat liver illness, malaria, sepsis, and Alzheimer's disease. Furthermore, the greater doses required for subcutaneous immunoglobulin use are expected to drive the demand in developed economies such as the United States. The annual cost of Subcutaneous Immunoglobulin (SCIG) treatment is around USD 40,000 in the region.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing applications of plasma proteins in the pharmaceutical industry is expected to boost the market growth.
  • Growing expenditure in the healthcare industry along with the introduction of new plasma-based therapies is estimated to fuel the market expansion in coming years.
  • Increasing demand for plasma-based therapies in emerging economies is attributed to provide the lucrative opportunities for the market players.
  • Technology advancement and growing adoption rate of new therapeutics in the sector is expected to accelerate the plasma protein therapeutic market growth.
  • Slower approval procedures and implementation of stringent regulation policies regarding plasma protein therapy are anticipated to hamper the market growth.

Scope of the Report

The report on the global plasma protein therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Plasma Protein Therapeutic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Immunoglobulin, Albumin, and Factor VIII), Applications (Primary Immunodeficiency Disorder, Hemophilia, Idiopathic Thrombocytopenic Purpura, and Others),

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Octapharma AG; CSL Behring LLC; Shire Plc; Grifols S.A.; Biotest AG; Bayer AG; and Kedrion S.P.A.

Market Segment Insights

Albumin segment is expected to expand at a robust pace

Based on products, the plasma protein therapeutic market is segmented immunoglobulin, albumin, and factor VIII.  The immunoglobulin segment is expected to account for a key share of the market in the coming years owing to the authorization of biologics for a variety of purposes, the convenience of administration, and the cost of treatment. However, the albumin segment is anticipated to expand at a rapid pace during the forecast period owing to improved diagnosis of hypoalbuminemia caused by cirrhosis of the liver and hepatitis B. High demand and usage in China, the world's largest market for albumin, are expected to fuel additional expansion.

Meanwhile, the factor VIII segment is projected to register a high CAGR during the forecast period as it is required as a prophylactic or on-demand medication for patients with moderate to severe haemophilia A. Around 70% of haemophilia patients, on the other hand, are receiving no or insufficient treatment. The replacement therapy Alpha-1 Antitrypsin (AAT) is used to treat a rare form of hereditary emphysema. Chronic obstructive pulmonary disease (COPD), bronchitis, and newborn hepatitis are all symptoms of the protein insufficiency. Currently, only roughly 10%-15% of AAT deficient individuals in the United States and Europe receive treatment, leaving possibility for the market expansion. Improvements in diagnostic rates and product introductions are expected to foster profitable growth in the entire segment.

Plasma Protein Therapeutic Market

PID segment is anticipated to register a substantial CAGR

In terms of applications, the market is segmented into primary immunodeficiency disorder [PID], hemophilia, idiopathic thrombocytopenic purpura [ITP], and others. The PID segment is expected to register a substantial CAGR during the forecast period owing to the increasing expansion of immunoglobulin clinical uses, approval of SCIGs. Meanwhile, the hemophilia segment is expected to represent a substantial growth rate due to increasing prevalence and rising demand for the diagnosis.

Plasma Protein Therapeutic Market

Asia Pacific is anticipated to dominate the market

On the basis of regions, the plasma protein therapeutic market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is anticipated to expand at an impressive CAGR and is likely to dominate the market during the forecast period. The regional market growth can be attributed to rising demand for efficient treatment alternatives, developing economies, and rising per capita income. These factors are listed to provide growth opportunities for market players in emerging countries. The market of North America, however, is projected to account for a key share of the market in the coming years owing to large patients’ base, growing geriatric population, and the availability of well-developed infrastructure for storing as well as keeping high-quality source plasma.

Plasma Protein Therapeutic Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Plasma Protein Therapeutic Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Plasma Protein Therapeutic Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Plasma Protein Therapeutic Market - Supply Chain
  4.5. Global Plasma Protein Therapeutic Market Forecast
     4.5.1. Plasma Protein Therapeutic Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Plasma Protein Therapeutic Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Plasma Protein Therapeutic Market Absolute $ Opportunity
5. Global Plasma Protein Therapeutic Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Plasma Protein Therapeutic Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Plasma Protein Therapeutic Demand Share Forecast, 2019-2026
6. North America Plasma Protein Therapeutic Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Plasma Protein Therapeutic Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Plasma Protein Therapeutic Demand Share Forecast, 2019-2026
7. Latin America Plasma Protein Therapeutic Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Plasma Protein Therapeutic Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Plasma Protein Therapeutic Demand Share Forecast, 2019-2026
8. Europe Plasma Protein Therapeutic Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Plasma Protein Therapeutic Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Plasma Protein Therapeutic Demand Share Forecast, 2019-2026
9. Asia Pacific Plasma Protein Therapeutic Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Plasma Protein Therapeutic Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Plasma Protein Therapeutic Demand Share Forecast, 2019-2026
10. Middle East & Africa Plasma Protein Therapeutic Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Plasma Protein Therapeutic Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Plasma Protein Therapeutic Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Plasma Protein Therapeutic Market: Market Share Analysis
  11.2. Plasma Protein Therapeutic Distributors and Customers
  11.3. Plasma Protein Therapeutic Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Octapharma AG CSL Behring LLC Shire Plc Grifols S.A. Biotest AG Bayer AG

Segments Covered in the Report

The global plasma protein therapeutic market has been segmented on the basis of

Products

  • Immunoglobulin
  • Albumin
  • Factor VIII

Applications

  • Primary Immunodeficiency Disorder (PID)
  • Hemophilia
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Octapharma AG
  • CSL Behring LLC
  • Shire Plc
  • Grifols S.A.
  • Biotest AG
  • Bayer AG
  • Kedrion S.P.A.

Key players competing in the global plasma protein therapeutic market are Octapharma AG; CSL Behring LLC; Shire Plc; Grifols S.A.; Biotest AG; Bayer AG; and Kedrion S.P.A. The immunoglobulin therapy Hizentra, used for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy, was approved by the Food and Drug Administration (FDA) in March 2018. The company's market supremacy is supported by superiority in China, differentiated product profile, the large number of plasma donor centres, and substantial fractionation capacity.

Plasma Protein Therapeutic Market

Buy Report